Noile-Immune Biotech (TSE:4893) Long-Term Capital Lease Obligation : 円0.0 Mil (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Noile-Immune Biotech Long-Term Capital Lease Obligation?

Noile-Immune Biotech's Long-Term Capital Lease Obligation for the quarter that ended in Jun. 2024 was 円0.0 Mil.

Noile-Immune Biotech Long-Term Capital Lease Obligation Historical Data

The historical data trend for Noile-Immune Biotech's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noile-Immune Biotech Long-Term Capital Lease Obligation Chart

Noile-Immune Biotech Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Noile-Immune Biotech Quarterly Data
	Dec20	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial					-	-	-	-	-

Noile-Immune Biotech (TSE:4893) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Noile-Immune Biotech Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Noile-Immune Biotech's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Noile-Immune Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noile-Immune Biotech Inc (TSE:4893) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

2-12-10 Shiba-Daimon, Minato-ku, Tokyo, JPN, 105-0012

Website

https://www.noile-immune.com

Noile-Immune Biotech Inc is engaged in the development of novel cancer immunotherapy including CAR-T cell therapy.

Noile-Immune Biotech Headlines

No Headlines